- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.02. | PrimeGen US and DT Cloud Star sign $1.5bn merger agreement | ||
| 04.02. | GSK oncology and HIV drugs leads to 7% sales rise in 2025 | ||
| 04.02. | Eli Lilly soars past expectations to hit 45% sales growth in 2025 | ||
| 04.02. | Novo Nordisk shares tumble 18% after 2026 sales dip warning | ||
| 04.02. | Relay Therapeutics' zovegalisib secures FDA BTD for advanced breast cancer | ||
| 04.02. | CEPI and Samsung Biologics partner to boost global vaccine preparedness | ||
| 03.02. | Pfizer sets sights on R&D strategy amid modest FY25 results | ||
| 03.02. | MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 | ||
| 03.02. | SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal | ||
| 03.02. | Aquestive receives FDA CRL for Anaphylm allergic reaction treatment | ||
| 02.02. | Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site | ||
| 02.02. | Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data | ||
| 02.02. | CHMP grants positive opinion for J&J's Akeega use | ||
| 02.02. | CIRM unveils RAPID funding programme for rare diseases | ||
| 30.01. | FDA's new scheme to boost US manufacturing commences despite uncertainty | ||
| 30.01. | Sanofi touts strong new launch sales amid looming Dupixent patent expiry | ||
| 30.01. | AstraZeneca signs $18.5bn weight loss drug deal with CSPC | ||
| 30.01. | IQVIA and Boehringer Ingelheim collaborate on therapeutic data transformation | ||
| 30.01. | Repertoire and Lilly join hands on autoimmune disease therapies | ||
| 29.01. | AstraZeneca pours $15bn into Chinese R&D and manufacturing operations | ||
| 29.01. | Roche's 2025 profit blunted by weakened US dollar | ||
| 29.01. | Sensorion announces $71.9m reserved offering to expand gene therapy pipeline | ||
| 29.01. | FDA grants breakthrough status to Biogen's litifilimab for CLE | ||
| 28.01. | Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership | ||
| 28.01. | CMS selects next batch of 15 high-cost medicines for third negotiation cycle |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.